Montelukast Cinfa

Montelukast, the active ingredient in Montelukast Cinfa, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma and allergic rhinitis in adults and children as part of maintenance therapy.

GNH USA supplies Montelukast Cinfa as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control inflammatory airway conditions. - Asthma (maintenance therapy): reduces frequency of bronchospasm and improves overall asthma control. - Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea. - Exercise‑induced bronchoconstriction: helps prevent airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Dyspepsia: indigestion or upset stomach. - Fever: low‑grade temperature elevation. - Sore throat: mild irritation.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis. - Neuropsychiatric events: mood changes, depression or suicidal thoughts. - Liver enzyme elevation: abnormal hepatic function tests. - Stevens‑Johnson syndrome: severe skin eruption. - Eosinophilic granulomatosis with polyangiitis: rare vasculitis. - Severe rash: widespread cutaneous eruptions.

Montelukast should be used with awareness of specific safety considerations. - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown; consider potential infant exposure. - Hepatic impairment: use with caution and monitor liver function. - Concomitant enzyme inducers: phenobarbital or rifampin may lower drug levels. - Neuropsychiatric symptoms: monitor for mood changes or suicidal thoughts. - Store below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital: may decrease plasma concentrations of montelukast. - Rifampin: can reduce therapeutic effect. - Strong CYP3A4 inducers: may lower drug exposure.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation. - Theophylline: potential increase in serum levels. - Zafirlukast: additive leukotriene inhibition; observe for enhanced effects.